<DOC>
	<DOCNO>NCT00948922</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Bortezomib add standard chemotherapy medicine ( ) treatment Multiple Myeloma .</brief_summary>
	<brief_title>Melphalan+Bortezomib Conditioning Regimen Autologous Allogeneic Stem Cell Transplants Multiple Myeloma</brief_title>
	<detailed_description>The primary objective study : - To determine 2 year-progression free survival multiple myeloma allogeneic transplant use condition regimen melphalan + fludarabine + Bortezomib patient &lt; 60 year age available HLA-matched donor compare 2 year-progression-free-survival autologous stem cell transplant melphalan+Bortezomib conditioning patient &lt; 60 year . - To determine 2 year-progression free survival multiple myeloma autologous stem cell transplant use condition regimen melphalan + Bortezomib . patient &gt; 60 year age patient &lt; 60 year age decline allogeneic stem cell transplant . The secondary objective study : - To determine overall survival multiple myeloma autologous allogeneic stem cell transplant use condition regimen - To determine response rate multiple myeloma use regimen . - To determine minimal residual disease status use allele specific oligonucleotides ( ASO-PCR ) PCR flow-cytometry multiple myeloma cell . - To correlate minimal residual disease status 2 year progression free survival overall survival . - To determine incidence acute chronic graft-versus-host disease ( GVHD ) multiple myeloma allogeneic stem cell transplant use condition regimen . - To examine quality life patient treat allogeneic autologous stem cell transplant use condition regimen .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Multiple Myeloma Criteria ( International Uniform Response Criteria Multiple Myeloma ) Patients responsive disease line induction therapy A complete response A good partial response A partial response Patients great equal 18 year age eligible . There upper age limit 60 year allogeneic transplant . Patients must histologically confirm diagnosis . All patient life expectancy least 12 week . Patients must undergo complete psychosocial evaluation consider capable compliance . Meet follow criterion allogeneic hematopoietic cell transplant : Must identify donor match define : HLAA , HLAB , HLA C , DRB1 8/8 allele match sibling , family member , unrelated donor . [ 7/8 would go separate mismatch trial ] &lt; 60 year age . Calculated hematopoietic cell transplantationspecific comorbidity index ( HCTCI ) &lt; 3 Patients achieve least partial response ( PR ) criterion mention induction therapy . Patient platelet count &lt; 30 x 10^9/L within 14 day enrollment . Patient &gt; /= Grade 2 peripheral neuropathy within 30 day enrollment . Patient absolute neutrophil count &lt; 1.0 x 10^9/L within 30 day enrollment . Myocardial infarction within 6 month prior enrollment New York Hospital Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant order subject consider eligible . Left ventricular ejection fraction ( LVEF ) multiple gated acquisition ( MUGA ) scan &lt; 40 % . Patient hypersensitivity bortezomib , boron mannitol . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . Patient receive investigational drug 30 day enrollment Serious medical psychiatric illness likely interfere participation clinical study . Patients diffuse capacity lung carbon monoxide ( DLCO ) less 50 % ( adjust ) normal symptomatic obstructive restrictive lung disease ineligible . Patients total bilirubin great 2.0 mg/dL exclude Gilbert 's syndrome serum glutamate oxaloacetate transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) great two half time normal ( unless due primary malignancy ) , history severe hepatic dysfunction ineligible . Calculated creatinine clearance &lt; /= 30 ml/min within 30 day enrollment Patients active infection ineligible . Patients HIV positive ineligible . Patients active leptomeningeal involvement ineligible . Patients history previous cerebrospinal fluid ( CSF ) tumor involvement without symptom sign eligible provide CSF free disease lumbar puncture , MRI brain show tumor involvement . Patients severe symptomatic central nervous system ( CNS ) disease etiology ineligible . Patients uncontrolled insulindependent diabetes mellitus define random glucose level &gt; 400 30 day prior initiation study therapy ; uncompensated major thyroid adrenal dysfunction ineligible . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; /= 2 ( Karnofsky &lt; 50 % ) ineligible . Patients ECOG performance status 2 3 ( Karnofsky 3050 % ) , secondary bone pain , may enrol . Patients ECOG performance status 2 3 ( Karnofsky 3050 % ) , secondary potentially reversible diseaserelated problem , may enrol . Patients previous malignancy nonmelanoma skin cancer ineligible , unless patient without evidence disease &gt; /= 5 year treatment cancer complete .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>myeloma</keyword>
	<keyword>myeloma protein</keyword>
	<keyword>autologous</keyword>
	<keyword>allogeneic</keyword>
</DOC>